Currently, the most effective and common cancer treatment is the use of chemotherapeutic drugs. When administered in high systemic doses, these drugs while treating malignant and metastatic cancer cells, can cause severe toxicity to healthy tissue cells, resulting in hair loss, nausea, and decreased immunity. One way to reduce this toxicity, while allowing high concentration of the drug to be delivered directly at the tumor site is through drug encapsulation into delivery particulates. Our ongoing research has focused on mesoporous inorganic-based silica particles as possible carriers for the anticancer agent, Doxorubicin (Dox). These mesoporous silicates were synthesized without and with the presence of organic functional groups (Sulfonate (SO3-Na+) and Carboxylate (CO2-Na+)) that can interact with Dox through an ion-exchange process and increase the capability of conjugating Dox. The non-functionalized (SBA), the sulfonate (SBA- SO3-Na+) and carboxylate (SBA- CO2-Na+) functionalized mesoporous silicate materials, were treated with aqueous solutions ofDoxorubicin in a 4:1 solid to drug weight ratio. Based on their Doxorubicin loading capacity, the materials can be ranked as follows: SBA- SO3-Na+ > SBA- CO2-Na+ > SBA, with SBA- SO3-Na+ capable of loading up to 200 mg of Doxorubicin per gram of solid. The release profiles of Doxorubicin from the three Dox-loaded materials in saline solution (0.9 wt% NaCl) were monitored at 37�C. The non-functionalized SBA material exhibits a rapid but incomplete (only 60%) and unreliable release of Dox.Doxorubicin releases completely from both SBA-SO3-DoxH+ and SBA-CO2-DoxH+. However, Dox releases with a slower release rate from SBA-SO3-DoxH+ thanfrom SBA-CO2-DoxH+.

Investigating mesoporous organosilicates as carriers for controlled delivery of the anticancer agent doxorubicin

239th National Meeting (2010)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.